SCHEMBL6351

SCHEMBL6351

COc1ccc(-c2ccc(C=O)cc2)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.86
CYP2A6 P11509 1/20 0.86
DRD1 P21728 1/20 0.57
HDAC8 Q9BY41 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
ESR2 Q92731 1/20 0.52
ALDH1A3 P47895 1/20 0.52
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19214399 1.00 ALDH1A1 (0.86) ALDH1A1CYP2A6DRD1HDAC8HDAC6
SCHEMBL14667871 0.94 ALDH1A1 (0.76) ALDH1A1CYP2A6DRD1HDAC8HDAC6
Anisaldehyde SCHEMBL1100 0.93 ALDH1A1 (1.00) ALDH1A1CYP2A6ALDH1A3LMNATP53
Anisaldehyde SCHEMBL717471 0.93 ALDH1A1 (1.00) ALDH1A1CYP2A6ALDH1A3LMNATP53
Anisaldehyde SCHEMBL1477047 0.91 ALDH1A1 (0.95) ALDH1A1CYP2A6ALDH1A3LMNATP53
Anisaldehyde SCHEMBL28776745 0.91 ALDH1A1 (0.95) ALDH1A1CYP2A6ALDH1A3LMNATP53
Anisaldehyde SCHEMBL28557435 0.91 ALDH1A1 (0.95) ALDH1A1CYP2A6ALDH1A3LMNATP53
Anisaldehyde SCHEMBL11255570 0.91 ALDH1A1 (0.95) ALDH1A1CYP2A6ALDH1A3LMNATP53
Anisaldehyde SCHEMBL1475478 0.91 ALDH1A1 (0.95) ALDH1A1CYP2A6ALDH1A3LMNATP53
Anisaldehyde SCHEMBL31123393 0.91 ALDH1A1 (0.95) ALDH1A1CYP2A6ALDH1A3LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184587-A Cyano-substituted benzimidazole luminescent compound and preparation method thereof 中国科学院化学研究所 2024-06-14 CN claimed
CN-118006117-A Long-life room-temperature phosphorescent nylon composite material and preparation method thereof 中国科学院化学研究所 2024-05-10 CN claimed
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors ORSOBIO INC (US) 2026-03-19 US disclosed
US-20250391519-A1 CHEMICAL SYNTHESIS PLATFORM UNIV GLASGOW COURT (GB) 2025-12-25 US disclosed
US-20250281515-A1 CARBORANE COMPOUNDS, CARBORANE ANALOGS, AND METHODS OF USE THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2025-09-11 US disclosed
EP-4548355-A1 CHEMICAL SYNTHESIS PLATFORM The University Court Of The University Of Glasgow (GB) 2025-05-07 EP disclosed
WO-2024226603-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-10-31 WO disclosed
CN-118184587-A Cyano-substituted benzimidazole luminescent compound and preparation method thereof 中国科学院化学研究所 2024-06-14 CN disclosed
CN-118006117-A Long-life room-temperature phosphorescent nylon composite material and preparation method thereof 中国科学院化学研究所 2024-05-10 CN disclosed
WO-2024003151-A1 CHEMICAL SYNTHESIS PLATFORM THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) 2024-01-04 WO disclosed
US-11802106-B2 Cathode buffer layer material and organic or organic/inorganic hybrid photoelectric device comprising same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2023-10-31 US disclosed
US-20030008768-A1 Catalyst for aromatic C-O, C-N, and C-C bond formation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-09 US disclosed
WO-2002096867-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG BIOMEDICAL INSTITUTE (US) 2002-12-05 WO disclosed
WO-2002094767-A2 TRISUBSTITUTED-N-[(1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS ABBOTT LABORATORIES (US) 2002-11-28 WO disclosed
US-20020173665-A1 Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors ABBOTT LABORATORIES 2002-11-21 US disclosed
EP-1248109-A1 Enantiomeric excess determination using a liquid crystal material Rijksuniversiteit te Groningen (NL) 2002-10-09 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002011883-A1 CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION YALE UNIVERSITY (US) 2002-02-14 WO disclosed
US-3996210-A OPTICAL BRIGHTENERS SANDOZ LTD. (CH) 1976-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173665-A1 Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors P2RX3, P2RX1, P2RX2 ALDH1A1 404/4885CYP2A6 2291/4885DRD1 796/4885
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors CPT1B, CBR1, MUSK ALDH1A1 290/4885CYP2A6 268/4885DRD1 1536/4885
US-11802106-B2 Cathode buffer layer material and organic or organic/inorganic hybrid photoelectric device comprising same DCX, CDH1, CACNA2D3 ALDH1A1 3065/4885CYP2A6 4656/4885DRD1 2219/4885
US-20250391519-A1 CHEMICAL SYNTHESIS PLATFORM SET, CBS, COASY ALDH1A1 2847/4885CYP2A6 440/4885DRD1 1416/4885
US-20250281515-A1 CARBORANE COMPOUNDS, CARBORANE ANALOGS, AND METHODS OF USE THEREOF ESR2, ESRRB, ESRRA ALDH1A1 1094/4885CYP2A6 761/4885DRD1 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.